Background and Objective: Adiponectin is produced by adipose cells and is considered an anti-inflammatory molecule. In contrast, C-reactive protein (CRP) has been identified as a hallmark of systemic inflammation and used as a risk marker of cardiovascular disease (CVD). Of interest was the relationship of these two biomarkers to oral health and CVD risk.
knowledge regarding how the oral health of the individual would impact the effectiveness of these biological measures.
Adiponectin is a circulating plasma protein produced abundantly and specifically by adipocytes and is detected at relatively high total levels in the bloodstream of humans that regulates the metabolism of lipids and glucose (1) (2) (3) (4) . Adiponectin is a major adipocyte-derived protein with antiinflammatory and anti-atherogenic properties affecting endothelial cells, thus appearing to play a protective role in atherosclerosis development and progression (5, 6) . C-reactive protein (CRP) is released systemically as part of the acute phase response to active inflammation, including infection, injury, neoplasia or chronic local inflammatory conditions, e.g. arthritis. Elevated CRP levels have been associated with an increased risk of heart attack and support the contribution of chronic inflammation to atherosclerotic vascular changes and coronary risk (7, 8) . Recent findings suggest that elevated CRP may be just as important as elevated low-density lipoprotein (LDL) cholesterol levels in predicting cardiovascular disease (CVD) risk, and that high CRP levels may identify high-risk patients (9) . Thus, CRP could be considered an independent marker of cardiovascular risk (10, 11) . These two mediators in serum appear to provide information regarding anti-inflammatory (e.g. adiponectin) and proinflammatory (e.g. CRP) responses that could link metabolic syndrome, obesity, diabetes and CVD.
Various studies have begun evaluating an array of biomolecules in saliva as a potential diagnostic fluid for both oral and systemic diseases (12) (13) (14) . Numerous reports have explored salivary profiles of analytes related to both oral (14) (15) (16) (17) and systemic diseases, including metabolic syndrome, diabetes, atherosclerosis and myocardial infarction (MI) (12) (13) (14) 18, 19) , with some of the studies including an assessment of oral disease. Furthermore, a fundamental basis in consideration of the utilization of saliva as a diagnostic fluid is some consistency/stability in alterations in levels of targeted analytes between health and disease (14, 20, 21) . In this regard, various reports have described this type of differentiation in health and disease, and the stability of selected analytes, similar to those evaluated in the current study (22, 23) . Kosaka et al. (24) recently demonstrated positive correlations of salivary cytokines, including interleukin-6, tumor necrosis factor a and prostaglandin E 2 with odds ratios of 2-3 for carotid atherosclerosis. Owing to its important cardiometabolic actions, adiponectin represents a biological molecule of interest and is a potential emerging biomarker of disease. Furthermore, CRP levels in serum and saliva have been identified related to CVD (25) (26) (27) (28) . Thus, we targeted these two biomolecules in various biological fluids of patients with MI that should enable additional information on their relationship to these clinical events and oral health of the individuals.
Material and methods

Patient recruitment
The rights of human subjects involved in this study were protected by the institutional review board of the research site. In all cases, informed (Beckman Coulter, Inc., Brea, CA, USA) consent was granted before sample collection. To ensure privacy rights of study participants, all samples were tested in a de-identified manner.
A cross-sectional clinical study was implemented, and 92 patients were recruited with acute MI (AMI), along with 111 age-and gender-matched non-AMI controls at hospitals of the University of Kentucky and University of Louisville. All patients with AMI were enrolled within 48 h of their cardiac event. Patients were classified as ST segment elevation MI (STEMI) based on ECG elevation of ST segments by À0.1 mV in contiguous leads in patients with ischemic symptoms and increased cardiac biomarkers (99th percentile of the upper reference limit for troponin I, cut-off 0.04 ng/mL). Diagnoses of non-STEMI (NSTEMI) were made for patients with ischemic symptoms and ECG changes consistent with ischemia (depression of the ST segments or new left bundle branch block), new pathologic Q-waves, or evidence of perfusion defects on stress test, and were followed by confirmatory positive troponin I test as a standard measure of myocardial damage. All study participants were at least 18 years old. Exclusion criteria were fever, stroke, immune disorders, use of steroid medications, organ complications/failure and inability to provide saliva. Demographic information was obtained (Table 1) , medical records reviewed, oral evaluation performed and biological fluids obtained (blood and unstimulated whole saliva [UWS]) from each study participant. Samples were transported on ice to a local laboratory, centrifuged and divided into aliquots. The specimens were generally kept on ice for < 1 h, before being stored at À80°C, and analyzed within 3 mo of collection.
As we have described previously, oral health was assessed visually at the bedside to not interfere with medical management of the patients with AMI or in the dental operatory for controls. Oral health was scored as poor, fair or good based similar to approaches used previously (29, 30) . Poor was defined as: generalized areas of mucosal inflammation, multiple broken down teeth, obvious tooth or gum infection or reports loose teeth. Fair was defined as: may have oral complaints, localized areas of mucosal inflammation, areas of visible decay, no obvious tooth or gum infection. Good was defined as: no complaints, no obvious mucosal inflammation, no reported loose teeth or symptoms of disease. Additionally, the number of teeth was determined as an estimate of past and existing dental disease (31) . Informed consent was granted before sample collection. To ensure privacy rights of study participants, all samples were de-identified and then assayed.
Sample collection and processing for analysis of serum and salivary analytes Two vacutainer tubes of blood were collected from each subject. One tube was sent to the University of Kentucky Chandler Medical Center Hospital Clinical Laboratory Improvement Amendments-approved laboratory for assessment of serum lipid levels. The second tube was processed for serum collection, aliquoted and stored frozen at À80°C. UWS samples (5 mL) were collected from each subject at baseline and at 4 (AE30 min) h post-procedure according to a modification of the method described by Navazesh (32) . Samples were collected into sterile tubes containing a protease inhibitor solution (SIGMAFAST; Sigma, St. Louis, MO, USA), then transported to the laboratory on ice, centrifuged, separated into aliquots and stored at À80°C until analyzed.
A Luminex IS-100 instrument was used for multiplexed detection of CRP and adiponectin with kits available from Beadlyte Technology (Millipore, St. Charles, MO, USA) (13) . All samples were analyzed in duplicate. Standards were included on all runs and results are reported within the linearity of the assays. The adiponectin assay range was 250-0.08 ng/mL with a minimal detectable dose of 0.056 ng/mL and the CRP assessment was 50-0.016 ng/mL with a minimal detectable dose of 0.0012 ng/ nL. These two host response molecules are studied in the context of serum and UWS for patients with AMI and compared to age-and gender-matched non-AMI control subjects.
Blood lipid levels were determined using a Beckman UniCel DxC 800 Synchron Clinical Systems instrument (Beckman Coulter, Inc., Brea, CA, USA) in the Clinical Laboratory Improvement Amendments-certified serum chemistry laboratory of the University of Kentucky Hospital.
Statistical analysis
Interval level demographic variables were presented as mean and standard deviation (SD) and categorical demographic variables as frequencies and percentages. Biomarker levels were presented as mean, median and SD. Percentages were compared among groups using chi-squared test statistics. Comparisons of means were based on one-way ANOVA, two-way ANOVA or two-sample t-tests depending on the number of groups being compared; each biomarker was log transformed in these comparisons. Pearson's correlations were based on log transformed biomarker data. Statistical analyses were performed using the PC SAS 9.2 (SAS Institute Inc., Cary, NC, USA) with significance determined at p < 0.05 level.
Results
Demographics of population Table 1 shows that the control subjects were slightly younger and were more likely to be female, but were comparable to patients with AMI on percentage white race, and percent reporting current alcohol use. As expected, the NSTEMI and STEMI groups had significantly more tobacco users than controls. Table 1 also shows that the AMI and control groups are comparable on mean body mass index (BMI), and triglyceride levels, but that the control group had elevated total cholesterol, LDL and high-density lipoprotein (HDL) levels compared to the AMI group (p < 0.004 in each case).
Adiponectin and C-reactive protein levels in acute myocardial infarction Figure 1A depicts the levels of adiponectin and CRP in serum and saliva from the AMI and control groups. As might be expected, CRP levels were significantly elevated in both serum and saliva of the patients with AMI (p < 0.0001, in each case) (8) . As expected based upon the vascular protective effects of adiponectin, significantly increased levels in the serum of the control group compared to the patients with AMI were observed (p = 0.0034). In contrast, the adiponectin levels were increased by about 50% in saliva from the patients with AMI, although this did not reach statistical significance (p = 0.58). Based on previous data (13) suggesting variations in levels of selected salivary analytes in patients with AMI presenting with STEMI compared to NSTEMI coronary events, the patients with AMI were stratified into these subsets. Here significantly increased levels of CRP in both the serum and saliva of patients with STEMI and NSTEMI compared to controls (p < 0.0001 in all cases) were observed (Fig. 1B) . In addition, the patients with STEMI showed significantly higher CRP concentrations compared to patients with NSTEMI (p = 0.0035 in both cases). A similar overview for serum adiponectin levels showed a stepwise decrease in adiponectin levels from control subjects through patients with STEMI (p = 0.0035, control vs. STEMI and p = 0.082 control vs. NTEMI). In contrast, saliva adiponectin levels were not significantly different among these three groups (p = 0.62).
Body mass index and lipids related to adiponectin and C-reactive protein Figure 2 explores the relationship between BMI and levels of serum and salivary adiponectin and CRP. Serum adiponectin levels were elevated in the controls compared to AMI in BMI tertiles 1 and 3, but not tertile 2 (p = 0.0075, 0.013 and 0.83, respectively). In contrast, saliva adiponectin did not vary systematically between controls and AMI in any tertile, although the control levels did decline with tertile. On the other hand, the levels of CRP were increased monotonically in AMI compared to controls in all tertiles for both serum and saliva (p < 0.003 in all cases) and in serum appeared to vary by tertile in both groups. Table 2 summarizes the observed relationships between the serum and salivary analytes, and the serum lipid levels. Adiponectin levels in serum and saliva were positively correlated with serum HDL and negatively correlated with serum triglyceride levels in the control subjects (p < 0.04 for each comparison). In the patients with AMI, salivary adiponectin levels were positively correlated with total cholesterol and LDL levels (p < 0.001 in both cases). With CRP, significant relationships were not noted in either biological fluid in either of the cohorts. Levels of both adiponectin and CRP in the two biological fluids were significantly positively correlated in the control subjects (p < 0.008 in both cases) and were positively correlated for adiponectin in the patients with AMI (p = 0.008). Oral health relationship to adiponectin and C-reactive protein Figure 3 summarizes the comparison of oral health in the control subjects and patients with AMI. The patients with AMI had significantly fewer teeth and significantly worse overall oral health than the control group (p < 0.0001 for each comparison). The relationship of serum and salivary adiponectin and CRP with the number of teeth in each patient was examined in the context of the severity of oral disease as shown in Fig. 4 . These data reveal significantly increasing levels of serum CRP in AMI subjects with increasing number of teeth. Serum CRP levels were significantly elevated in patients with AMI compared to controls irrespective of the number of teeth present (p < 0.03 for each subgroup). Salivary CRP was also increased in the AMI vs. control subjects in the lowest and highest subgroups (p < 0.008 in both cases but not the middle subgroup). Figure 4 also depicts adiponectin levels. In serum, control levels of adiponectin are elevated for the two subgroups with the most teeth (p < 0.02 in both comparisons) while salivary adiponectin levels were elevated in the AMI group compared to the controls in only the highest subgroup (p = 0.02).
Discussion
The BMI levels were similar in the AMI and control groups, which may be expected, as the control patients were selected from family and acquaintances of the patients with the cardiac events enlisted into the study. However, the patients with AMI had significantly fewer teeth and significantly worse oral health than the control group, consistent with some of the existing literature supporting worse oral health in patients with CVDs and the potential linkage of chronic infection and inflammation in the oral cavity contributing to systemic risk changes for CVD (33) (34) (35) (36) (37) . Consistent with the documented elevation in CRP levels in patients at risk for CVD events (9), the levels were significantly elevated in both serum and saliva of the patients with AMI. Of particular interest, was the observation that even using a control population with a number of existing risk factors for CVD, CRP was significantly elevated above the controls in both fluids from the patients who had a cardiac event. These findings were even more pronounced with levels of CRP in the serum and saliva of patients with STEMI and NSTEMI compared to controls, whereby patients with STEMI showed the greatest levels of CRP. This finding is consistent with the patients with STEMI generally considered to have a more severe MI and tissue damage (38) . As the samples were collected within 48 h of the event, we cannot determine whether these elevated CRP levels presaged the AMI or if this molecule increased rapidly postischemia, or both, and is a limitation of this investigation. Adiponectin exerts anti-inflammatory effects via macrophages by suppressing the production of proinflammatory cytokines (1) and contributing to a significant reduction of the risk of MI, even after correction for HDL-and LDL-cholesterol and BMI (39) . In non-diabetic subjects, levels of adiponectin are inversely related to CVD severity (4) and low plasma adiponectin is associated with an early onset of coronary heart disease emphasizing that adiponectin is influenced by body fat status and associated with CVD (40) . Adiponectin has also been reported to be negatively correlated with plasma triglycerides and positively correlated with HDL (3, 5) . The present study demonstrated that adiponectin levels were significantly increased in the serum of controls vs. patients with AMI, which might be expected from the existing literature. Moreover, the serum adiponectin levels were lowest in the patients with STEMI, consistent with a lower level of this protective adipokine in patients with the most severe cardiac events.
The adiponectin and CRP levels were inversely related within these populations, similar to a report by George et al. (41) showing a negative relationship of serum adiponectin and CRP levels, reflecting an increased risk indicator of CVD. Plasma adiponectin levels are decreased in obesity (39, 42, 43) . We observed lower levels of serum adiponectin and higher levels of CRP in both control subjects and the patients with AMI related to the BMI of the individuals. This is consistent with an increased level of obesity coincident with decreased systemic adiponectin, which would represent an anti-inflammatory protective factor for CVD in the patients. Moreover, the proinflammatory aspects of excess adipose tissue would be expected to contribute to adverse levels of CRP in the serum that has been demonstrated as a predictive risk indicator for CVD (9, 11, 44 ). An accompanying interesting interpretation of these findings was that this relationship existed in both the control subjects and patients with AMI. As noted previously, we deliberately selected a control population, as not inherently CVD normal, but one that was similar to the patients with AMI in demographic and clinical features, absent a cardiac event. The results then would imply that a number of the "control" patients demonstrated multiple risk markers for a future ischemic event.
Some previous studies have identified adiponectin in saliva (45, 46) found a significant correlation between salivary and serum adiponectin in healthy male volunteers > 43 years of age. A more recent study confirmed this relationship in both genders, as well as younger subjects (48) . We observed that salivary adiponectin levels decreased in the patients with AMI with increased BMI. Thus, there appears to be a reflection of the host responses to obesity that is reflected in both the serum and saliva of the subjects, albeit, the existence of a cardiac event modulates these responses. Nigro et al. (47) recently evaluated adiponectin levels in saliva are related to obesity and show a higher expression of both high and low molecular weight forms in saliva from obese patients, suggesting a potential for salivary biomarkers in metabolic disorders. Elevated salivary CRP levels (sixfold) and decreased adiponectin levels (30%) were noted in obese children (49) . Saliva and serum adiponectin levels were correlated and plasma adiponectin was decreased with increased triglyceride levels and waist circumference in patients with the metabolic syndrome (50) , and a report on correlations in salivary and serum CRP and adiponectin in postmenopausal women (51) .
The adipokines (resistin, visfatin and adiponectin) were examined in the saliva of healthy individuals and showed a significant correlation between adiponectin in the saliva and serum of healthy subjects, but provided no insight into variations of this biomolecule related to disease, or risk of disease (48) . In the present study, both adiponectin and CRP levels were significantly positively correlated in the biological fluids from the control subjects suggesting that the salivary levels of the molecules likely reflect a direct serum contribution to the oral cavity irrespective of the level of oral health or disease. Interestingly, this relationship was lost in the patients with AMI.
A study identified a substantial increase in periodontitis in patients with AMI, associated with elevations in serum CRP, but not adiponectin (52) . In the PAROKRANK study (Periodontitis and Its Relation to Coronary Artery Disease), in patients with an initial myocardial infarct the levels of matrix metalloproteinase-8 and myeloperoxidase were elevated in patients with non-MI vs. MI and primarily correlated with clinical signs of periodontal inflammation (53) . Salivary CRP levels have been shown to be correlated with arterial blood pressure, BMI and intima-media thickness, as was matrix metalloproteinase-9 in saliva. Lipid inflammatory mediators (leukotriene B 4 , prostaglandin E 2 ) in saliva were also associated with arterial stiffness (54) . Salivary malondialdehyde levels (a measure of lipid peroxidation) were elevated in both patients with chronic adult periodontitis and acute coronary syndrome. These levels also correlated with periodontal clinical parameters and levels of serum CRP and fibrinogen (55) . Furthermore, a recent case-control study identified significantly elevated salivary CRP levels in the periodontitis group (56) .
Significantly increased levels of serum CRP in the control subjects was related to increasing numbers of teeth. In contrast, serum CRP levels were significantly elevated in patients with AMI compared to controls irrespective of the number of teeth present. Control subjects with the fewest teeth had the lowest serum adiponectin levels and the AMI group presented a profile of adiponectin that was generally unaffected by the number of teeth present. Salivary adiponectin levels were generally increased in both controls and patients with AMI with increasing number of teeth, while salivary CRP was only elevated in patients with AMI with the greatest number of teeth. These findings indicate a relationship of the inflammatory (CRP) and anti-inflammatory (adiponectin) biomolecules with BMI, and an association of these levels that relate to tooth number and potentially reflect the level of oral health. Interestingly, studies have also demonstrated that oral bacterial stimulation of periodontal cells can induce local production of adiponectin (57) . Moreover, administration of adiponectin in a murine periodontitis model reduced alveolar bone loss, reflecting altered osteoclastogenesis with decreased osteoclast numbers (58), thus supporting some relationship between these biomolecules and biological processes occurring in the oral cavity.
While a limitation of the study could be perceived to be related to the predominant Caucasian distribution of the population, the overall profile of our study group was in the range of the 75% US and 90% Kentucky race/ethnicity population base. Moreover, a potential confounder in the clinical assessment of the subjects, was the potential that dental services were provided immediately preceding entry into the study and could affect these measures, as well as the potential that following AMI, general oral hygiene practices could be substantially altered leading to a readout of worse oral health. The clinical evaluation of the patients with AMI was conducted within 48 h of the event, thus, we feel it unlikely that this interval would have minimal impact on the tooth numbers and overall oral health categorization. Additionally, while it is possible that the control group had a greater number of individuals that had received recent dental prophylaxis vs. the patients with AMI, we accessed the control group from the general subject pool of individuals as represented by the patients with AMI. Thus, we believe it is unlikely that the access to active professional dental services significantly affected the overall oral health evaluation between the two groups, and we cannot eliminate this confounder with the data available. These findings provide insight into the interrelationships of a systemic anti-inflammatory and proinflammatory biomarker in patients with AMI, including documenting difference in levels of these analytes in UWS that could contribute to profiling the biologic risk of individuals for cardiac events.
